Efficiency Comparison of Direct Reprogramming CD34<sup>+</sup> Cells into Cardiomyocytes Using Cardiomyocyte Differentiation Medium vs MicroRNA-1

Andrianto, Andrianto; Pikir, Budi Susetyo; Ferdiansyah,; Pristianto, Tinton; Hermawan, Hanestya Oky; Zaini, Bagas Setiawan Ihsan; Muhammad, Akbar Reza

doi:10.1089/cell.2021.0075

Cited by 2 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During myocardial injury, broblasts will be active and migrate to the site of injury to maintain the structural integrity of the heart by inducing brosis. This leaves non-contractile areas in the heart, which result in worsened ventricular function and contribute to remodeling and increased stiffness of the heart 4 .…”

Section: Introductionmentioning

confidence: 99%

“…MicroRNA (miRNA) plays an important role in cardiovascular disease, including heart failure. MicroRNA is a non-coding (non-coding) RNA that works at the post-transcriptional stage by degrading or inhibiting target messenger RNA (mRNA) translation, which results in the modi cation of gene expression 4 . MicroRNA is also detected in the circulation and is stable, meaning it has the potential to be used as a diagnostic and prognostic biomarker in HFpEF patients 5 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Andrianto,

Al-Farabi,

Arifitrianto

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Currently, there is an unmet need for a minimally invasive diagnostic tool with less radiation for the early development of myocardial fibrosis and targeted treatment for preserved ejection fraction (HFpEF). This study aimed to investigate the diagnostic potential of circulating microRNAs (miRNAs) for detecting early myocardial fibrosis development in HFpEF patients. Methods: This observational study used a case-control research design. Peripheral blood samples were isolated from 25 HFpEF patients and 25 normal patients. They were measured for complete laboratory testing, NTproBNP levels using ELISA, as well as MicroRNA-1, 21, and 29 levels using RT-PCR. All patients also underwent echocardiography for global longitudinal strain (GLS) to measure the myocardial fibrosis progression. Data were analyzed using SPSS 25.0. Results: HFpEF patients had significantly higher GLS compared to the normal patients (-13±2.4% vs -19±3.2%; p < 0.05), suggesting HFpEF patients tended to have myocardial fibrosis. HFpEF patients also had significantly higher microRNA-1 and microRNA-21 compared to the normal patients (p < 0.05), but they had lower microRNA-1 (p < 0.05). There was a positive correlation between microRNA-1 (r = 0.753; p < 0.05) and microRNA-21 (r = 0.675; p < 0.05) and an inverse correlation with microRNA-29 (r = -0.653; p < 0.05) based on the GLS findings. By using a GLS cutoff of -15% for myocardial fibrosis, microRNA-1, microRNA-21, and microRNA-29 were found to be able to predict myocardial fibrosis based on GLS with a specificity of 78% and sensitivity of 75%. Conclusion: Increasing microRNA-1 and microRNA-21 followed by decreasing microRNA-29 in HFpEF patients suggest early myocardial fibrosis. Detection of those biomarkers can be beneficial for early myocardial fibrosis diagnosis, early aggressive HFpEF treatment, and targeted miRNA silencing therapy to prevent worsening HFpEF.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Andrianto,

Al-Farabi,

Arifitrianto

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…During myocardial injury, fibroblasts will be active and migrate to the site of injury to maintain the structural integrity of the heart by inducing fibrosis. This leaves non-contractile areas in the heart, which result in worsened ventricular function and contribute to remodeling and increased stiffness of the heart [4].…”

Section: Introductionmentioning

confidence: 99%

“…MicroRNA (miRNA) plays an important role in cardiovascular disease, including heart failure. MicroRNA is a non-coding (non-coding) RNA that works at the post-transcriptional stage by degrading or inhibiting target messenger RNA (mRNA) translation, which results in the modification of gene expression [4]. MicroRNA is also detected in the circulation and is stable, meaning it has the potential to be used as a diagnostic and prognostic biomarker in HFpEF patients [5].…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Andrianto,

Al-Farabi,

Arifitrianto

et al. 2023

Preprint

View full text Add to dashboard Cite

This study aimed to investigate the diagnostic potential of circulating microRNAs (miRNAs) for detecting early myocardial fibrosis development in HFpEF patients. This observational study used a case-control research design. Peripheral blood samples were isolated from 25 HFpEF patients and 25 normal patients. They were measured for NTproBNP levels using ELISA, as well as MicroRNA-1, 21, and 29 levels using RT-PCR. All patients also underwent echocardiography for global longitudinal strain (GLS) to measure the myocardial fibrosis progression. Data were analyzed using SPSS 25.0. HFpEF patients had significantly higher GLS compared to the normal patients (-13±2.4% vs -19±3.2%; p &lt; 0.05), suggesting HFpEF patients tended to have myocardial fibrosis. HFpEF patients also had significantly higher microRNA-1 and microRNA-21 compared to the normal patients (p &lt; 0.05), but they had lower microRNA-1 (p &lt; 0.05). There was a positive correlation between microRNA-1 (r = 0.753; p &lt; 0.05) and microRNA-21 (r = 0.675; p &lt; 0.05) and an inverse correlation with microRNA-29 (r = -0.653; p &lt; 0.05) based on the GLS findings. By using a GLS cutoff of -15% for myocardial fibrosis, microRNA-1, microRNA-21, and microRNA-29 were found to be able to predict myocardial fibrosis based on GLS with a specificity of 78% and sensitivity of 75%. Increasing microRNA-1 and microRNA-21 followed by decreasing microRNA-29 in HFpEF patients suggest early myocardial fibrosis.

show abstract

Efficiency Comparison of Direct Reprogramming CD34⁺ Cells into Cardiomyocytes Using Cardiomyocyte Differentiation Medium vs MicroRNA-1

Cited by 2 publications

References 18 publications

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Contact Info

Product

Resources

About

Efficiency Comparison of Direct Reprogramming CD34+ Cells into Cardiomyocytes Using Cardiomyocyte Differentiation Medium vs MicroRNA-1

Cited by 2 publications

References 18 publications

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Diagnostic Potential of MicroRNA-1, MicroRNA-21, and MicroRNA-29 as Novel Biomarkers for Early Development of Myocardial Fibrosis in Heart Failure with Preserved Ejection Fraction

Contact Info

Product

Resources

About

Efficiency Comparison of Direct Reprogramming CD34⁺ Cells into Cardiomyocytes Using Cardiomyocyte Differentiation Medium vs MicroRNA-1